Enveric Biosciences has received a second Notice of Allowance from the United States Patent and Trademark Office for its EVM401 Series. This patent covers novel, non-hallucinogenic mescaline derivatives designed to modulate neurotransmitters relevant to neuropsychiatric disorders. The compounds are inspired by methylone but are structurally differentiated to ensure strong intellectual property protection. This advancement strengthens Enveric's position in developing neuroplastogenic small-molecule therapeutics aimed at treating mental health disorders such as PTSD. Further preclinical testing is anticipated to assess the safety and efficacy of these compounds.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。